Xenon Pharmaceuticals develops therapies for neurological disorders, with a pipeline targeting epilepsy and related ...
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) is one of the 10 Best Performing Canadian Stocks So Far in 2026. On May 12, 2026, JPMorgan analyst Tessa Romero raised the firm’s price target on Xenon ...
A phase 3 trial presented at the American Academy of Neurology meeting found azetukalner, a novel Kv7 channel opener, significantly reduced focal onset seizures in adults within one week of treatment.
Azetukalner data show significant reductions in seizure frequency across weekly, monthly and multi-year time points X-TOLE2 data featured in Late-breaking Science session show 53.2% reduction in ...
Xenon Pharmaceuticals (XENE) announced new data highlighting its commitment in epilepsy, including interim 48-month data from its ongoing X-TOLE open-label extension, OLE, study of azetukalner in ...
Shares of Xenon Pharmaceuticals Inc. soared as the company’s top-line readout of the phase III X-Tole2 study testing azetukalner in focal onset seizures (FOS) solidly bested expectations, positioning ...
Biohaven Ltd. (NYSE:BHVN) is one of the 7 best small-cap healthcare stocks to buy according to hedge funds. On March 11, Ken Cacciatore from TD Cowen increased the price target on Biohaven Ltd.
Azetukalner data show significant reductions in seizure frequency across weekly, monthly and multi-year time points X-TOLE2 data featured in Late-breaking Science session show 53.2% reduction in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results